{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Placebo+%28Sterile+Normal+Saline%29&page=6",
    "query": {
      "intervention": "Placebo (Sterile Normal Saline)",
      "page": 6
    },
    "page_size": 10
  },
  "pagination": {
    "page": 6,
    "page_size": 10,
    "total_count": 425,
    "total_pages": 43,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Placebo+%28Sterile+Normal+Saline%29&page=7&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Placebo+%28Sterile+Normal+Saline%29&page=5&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-14T02:01:11.348Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT02825797",
      "title": "3BNC117 and 10-1074 in HIV-infected Individuals",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Human Immunodeficiency Virus (HIV)"
      ],
      "interventions": [
        {
          "name": "3BNC117",
          "type": "DRUG"
        },
        {
          "name": "10-1074",
          "type": "DRUG"
        },
        {
          "name": "Analytical treatment interruption",
          "type": "OTHER"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Rockefeller University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 34,
      "start_date": "2016-06",
      "completion_date": "2018-08-15",
      "has_results": false,
      "last_update_posted_date": "2018-08-21",
      "last_synced_at": "2026-10-14T02:01:11.348Z",
      "location_count": 1,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02825797"
    },
    {
      "nct_id": "NCT02939742",
      "title": "Does a Rescue Course of Betamethasone in Pregnant Women With PPROM Decrease Neonatal Morbidity?",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2",
        "PHASE3"
      ],
      "conditions": [
        "PPROM",
        "Respiratory Distress Syndrome in Premature Infants"
      ],
      "interventions": [
        {
          "name": "Betamethasone",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "The University of Texas Medical Branch, Galveston",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "50 Years",
        "sex": "FEMALE",
        "summary": "18 Years to 50 Years · Female only"
      },
      "enrollment_count": 33,
      "start_date": "2016-11",
      "completion_date": "2023-12-20",
      "has_results": true,
      "last_update_posted_date": "2026-06-30",
      "last_synced_at": "2026-10-14T02:01:11.348Z",
      "location_count": 1,
      "location_summary": "Galveston, Texas",
      "locations": [
        {
          "city": "Galveston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02939742"
    },
    {
      "nct_id": "NCT03222973",
      "title": "Efficacy and Safety of BIIB033 (Opicinumab) as an Add-on Therapy to Disease-Modifying Therapies (DMTs) in Relapsing Multiple Sclerosis (MS)",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Multiple Sclerosis"
      ],
      "interventions": [
        {
          "name": "BIIB033 (opicinumab)",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Biogen",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "58 Years",
        "sex": "ALL",
        "summary": "18 Years to 58 Years"
      },
      "enrollment_count": 263,
      "start_date": "2017-11-15",
      "completion_date": "2021-02-12",
      "has_results": true,
      "last_update_posted_date": "2022-04-28",
      "last_synced_at": "2026-10-14T02:01:11.348Z",
      "location_count": 51,
      "location_summary": "Cullman, Alabama • Gilbert, Arizona • Berkeley, California + 44 more",
      "locations": [
        {
          "city": "Cullman",
          "state": "Alabama"
        },
        {
          "city": "Gilbert",
          "state": "Arizona"
        },
        {
          "city": "Berkeley",
          "state": "California"
        },
        {
          "city": "Long Beach",
          "state": "California"
        },
        {
          "city": "Newport Beach",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03222973"
    },
    {
      "nct_id": "NCT05393037",
      "title": "Safety and Immunogenicity of V116 in Adults Living With Human Immunodeficiency Virus (HIV) (V116-007, STRIDE-7)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Pneumococcal Disease"
      ],
      "interventions": [
        {
          "name": "V116",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo",
          "type": "BIOLOGICAL"
        },
        {
          "name": "PCV15",
          "type": "BIOLOGICAL"
        },
        {
          "name": "PPSV23",
          "type": "BIOLOGICAL"
        },
        {
          "name": "PCV15 - Part B",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Merck Sharp & Dohme LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 313,
      "start_date": "2022-07-13",
      "completion_date": "2024-01-25",
      "has_results": true,
      "last_update_posted_date": "2026-02-05",
      "last_synced_at": "2026-10-14T02:01:11.348Z",
      "location_count": 7,
      "location_summary": "Phoenix, Arizona • Washington D.C., District of Columbia • Ft. Pierce, Florida + 4 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "Ft. Pierce",
          "state": "Florida"
        },
        {
          "city": "Orlando",
          "state": "Florida"
        },
        {
          "city": "Kansas City",
          "state": "Missouri"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05393037"
    },
    {
      "nct_id": "NCT07721922",
      "title": "Efficacy of Nebulized Long-Acting Bronchodilators (Formoterol and Revefenacin) vs. Short-Acting Bronchodilators (Albuterol and Ipratropium) in Patients Presenting to the Emergency Department With Acute Exacerbation of COPD (ECOPD)",
      "overall_status": "NOT_YET_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "COPD Exacerbation"
      ],
      "interventions": [
        {
          "name": "Revefenacin",
          "type": "DRUG"
        },
        {
          "name": "formoterol fumarate",
          "type": "DRUG"
        },
        {
          "name": "Placebo (Sterile Normal Saline)",
          "type": "OTHER"
        },
        {
          "name": "Albuterol sulfate",
          "type": "DRUG"
        },
        {
          "name": "Ipratropium Bromide",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "University of Tennessee Graduate School of Medicine",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "40 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "40 Years and older"
      },
      "enrollment_count": 280,
      "start_date": "2026-09-01",
      "completion_date": "2028-09-01",
      "has_results": false,
      "last_update_posted_date": "2026-08-17",
      "last_synced_at": "2026-10-14T02:01:11.348Z",
      "location_count": 1,
      "location_summary": "Knoxville, Tennessee",
      "locations": [
        {
          "city": "Knoxville",
          "state": "Tennessee"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07721922"
    },
    {
      "nct_id": "NCT02543268",
      "title": "A Study to Evaluate the Immunogenicity, Safety and Tolerability of Ad26.ZEBOV and MVA-BN-Filo in Healthy Adult Participants",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Healthy"
      ],
      "interventions": [
        {
          "name": "Ad26.ZEBOV-Batch #1",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Ad26.ZEBOV-Batch #2",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Ad26.ZEBOV-Batch #3",
          "type": "BIOLOGICAL"
        },
        {
          "name": "MVA-BN-Filo",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Crucell Holland BV",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "50 Years",
        "sex": "ALL",
        "summary": "18 Years to 50 Years"
      },
      "enrollment_count": 329,
      "start_date": "2015-09-21",
      "completion_date": "2016-07-20",
      "has_results": false,
      "last_update_posted_date": "2025-06-22",
      "last_synced_at": "2026-10-14T02:01:11.348Z",
      "location_count": 6,
      "location_summary": "Huntsville, Alabama • San Diego, California • Melbourne, Florida + 3 more",
      "locations": [
        {
          "city": "Huntsville",
          "state": "Alabama"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "Melbourne",
          "state": "Florida"
        },
        {
          "city": "Peoria",
          "state": "Illinois"
        },
        {
          "city": "Mishawaka",
          "state": "Indiana"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02543268"
    },
    {
      "nct_id": "NCT03649724",
      "title": "The LUCINDA Trial: LeUprolide Plus Cholinesterase Inhibition to Reduce Neurological Decline in Alzheimer's",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Alzheimer Disease",
        "Mild Cognitive Impairment"
      ],
      "interventions": [
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "Eligard 22.5Mg Suspension for Injection",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Weill Medical College of Cornell University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "60 Years",
        "maximum_age": "120 Years",
        "sex": "FEMALE",
        "summary": "60 Years to 120 Years · Female only"
      },
      "enrollment_count": 86,
      "start_date": "2020-11-27",
      "completion_date": "2026-07-25",
      "has_results": false,
      "last_update_posted_date": "2026-09-21",
      "last_synced_at": "2026-10-14T02:01:11.348Z",
      "location_count": 3,
      "location_summary": "Boca Raton, Florida • New York, New York • Madison, Wisconsin",
      "locations": [
        {
          "city": "Boca Raton",
          "state": "Florida"
        },
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "Madison",
          "state": "Wisconsin"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03649724"
    },
    {
      "nct_id": "NCT02927431",
      "title": "Study to Evaluate the Efficacy and Safety of Danirixin Co-administered With Oseltamivir in the Treatment of Adults Hospitalized With Influenza",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Virus Diseases"
      ],
      "interventions": [
        {
          "name": "Danirixin 15 mg FBE",
          "type": "DRUG"
        },
        {
          "name": "Danirixin 50 mg FBE",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "Oseltamivir 75 mg",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "GlaxoSmithKline",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 10,
      "start_date": "2017-01-19",
      "completion_date": "2017-05-24",
      "has_results": true,
      "last_update_posted_date": "2020-11-30",
      "last_synced_at": "2026-10-14T02:01:11.348Z",
      "location_count": 5,
      "location_summary": "Stamford, Connecticut • Council Bluffs, Iowa • Natchitoches, Louisiana + 2 more",
      "locations": [
        {
          "city": "Stamford",
          "state": "Connecticut"
        },
        {
          "city": "Council Bluffs",
          "state": "Iowa"
        },
        {
          "city": "Natchitoches",
          "state": "Louisiana"
        },
        {
          "city": "Durham",
          "state": "North Carolina"
        },
        {
          "city": "Salem",
          "state": "Virginia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02927431"
    },
    {
      "nct_id": "NCT02215200",
      "title": "ATG-GCSF in New Onset Type 1 Diabetes",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Diabetes Mellitus, Type 1"
      ],
      "interventions": [
        {
          "name": "Anti-Thymocyte Globulin (ATG)",
          "type": "DRUG"
        },
        {
          "name": "Granulocyte colony stimulating factor (GCSF)",
          "type": "DRUG"
        },
        {
          "name": "Placebo (for ATG)",
          "type": "DRUG"
        },
        {
          "name": "Placebo (for GCSF)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": "45 Years",
        "sex": "ALL",
        "summary": "12 Years to 45 Years"
      },
      "enrollment_count": 89,
      "start_date": "2014-12",
      "completion_date": "2018-08",
      "has_results": true,
      "last_update_posted_date": "2020-03-02",
      "last_synced_at": "2026-10-14T02:01:11.348Z",
      "location_count": 13,
      "location_summary": "San Francisco, California • Stanford, California • Aurora, Colorado + 10 more",
      "locations": [
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Stanford",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "New Haven",
          "state": "Connecticut"
        },
        {
          "city": "Gainesville",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02215200"
    },
    {
      "nct_id": "NCT03852992",
      "title": "Laser Assisted Delivery of Minoxidil in Androgenetic Alopecia",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Male Pattern Hair Loss",
        "Androgenetic Alopecia",
        "Male Pattern Baldness"
      ],
      "interventions": [
        {
          "name": "Post-Laser Minoxidil 2%",
          "type": "DRUG"
        },
        {
          "name": "At-Home Minoxidil 5%",
          "type": "DRUG"
        },
        {
          "name": "Laser",
          "type": "DEVICE"
        },
        {
          "name": "Post-laser 5mg minoxidil",
          "type": "DRUG"
        },
        {
          "name": "Post-laser 10mg minoxidil",
          "type": "DRUG"
        },
        {
          "name": "Post-laser 20mg minoxidil",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG",
        "DEVICE"
      ],
      "sponsor": "University of Minnesota",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "21 Years",
        "maximum_age": "65 Years",
        "sex": "MALE",
        "summary": "21 Years to 65 Years · Male only"
      },
      "enrollment_count": 0,
      "start_date": "2022-09-30",
      "completion_date": "2023-07-01",
      "has_results": false,
      "last_update_posted_date": "2023-09-13",
      "last_synced_at": "2026-10-14T02:01:11.348Z",
      "location_count": 1,
      "location_summary": "Minneapolis, Minnesota",
      "locations": [
        {
          "city": "Minneapolis",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03852992"
    }
  ]
}